Evolus announced the publication of the European and Canadian Phase III head-to-head pivotal trial results in the April issue of Aesthetic Surgery Journal. “The results of this study are compelling and reinforce the clinical performance of Jeuveau, which is the first 900 kDa product to enter the U.S. market in nearly 30 years,” said David Moatazedi, president and CEO. “We look forward to launching Jeuveau in the coming weeks in the United States.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.